Abbott Pakistan profit surges 36% to Rs5bn in 9MCY25

October 29, 2025 (MLN): Abbott Laboratories (Pakistan) Limited (PSX: ABOT) reported a net profit of Rs5.37bn for the nine months ended September 30, 2025, up 36% from Rs3.95bn in the corresponding period last year.

Earnings per share increased 36% to Rs54.81 compared to Rs40.34 in 9MCY24.

Net sales rose 13% year-on-year to Rs56.23bn from Rs49.56bn, driven by robust domestic demand. Local sales grew 14% to Rs53.91bn from Rs47.27bn, while export sales increased marginally by 1% to Rs2.32bn from Rs2.29bn.

Cost of sales increased 4% to Rs36.89bn from Rs35.49bn, resulting in a gross profit surge of 37% to Rs19.34bn against Rs14.07bn in 9MCY24.

Selling and distribution expenses climbed 19% to Rs8.50bn from Rs7.12bn last year. Administrative expenses rose 13% to Rs972.5m from Rs857.4m in the prior period.

Other charges more than doubled, increasing 117% to Rs1.26bn from Rs578.9m in 9MCY24. Other income grew 12% to Rs603.3m from Rs541.1m.

Profit before taxation increased 52% to Rs9.16bn from Rs6.04bn in 9MCY24.

Minimum tax differential rose 68% to Rs147.0m from Rs87.3m. Profit after taxation stood at Rs9.01bn, up 51% from Rs5.95bn last year.

The company concluded 9MCY25 with a net profit of Rs5.37bn.

The strong profit growth was primarily driven by a 14% expansion in local sales and improved gross margins despite higher distribution costs, showing Abbott's solid market position in Pakistan's pharmaceutical sector and effective cost management strategies during the period.

Copyright Mettis Link News